|1.||Ikawa, Kazuro: 6 articles (02/2013 - 02/2008)|
|2.||Morikawa, Norifumi: 6 articles (02/2013 - 02/2008)|
|3.||Kohno, Shigeru: 4 articles (09/2013 - 01/2008)|
|4.||Ikeda, Kayo: 4 articles (12/2011 - 02/2008)|
|5.||Yanagihara, Katsunori: 3 articles (09/2013 - 01/2008)|
|6.||Izumikawa, Koichi: 3 articles (09/2013 - 01/2008)|
|7.||Karino, Fumi: 2 articles (10/2013 - 02/2013)|
|8.||Ohe, Miki: 2 articles (10/2013 - 02/2013)|
|9.||Isobe, Takeshi: 2 articles (10/2013 - 02/2013)|
|10.||Kuraki, Takashige: 2 articles (10/2013 - 02/2013)|
01/01/1996 - "The present study shows that biapenem may be useful in the treatment of intra-abdominal infections."
03/01/2000 - "These results suggest that the new antimicrobial agent biapenem might be useful for the treatment of polymicrobial infections in the fields of obstetrics and gynecology."
02/01/1995 - "Biapenem seems to be useful in the treatment of intraabdominal infections."
12/01/1994 - "3. The results above indicate that L-627 is useful for the treatment of general infections in pediatrics."
01/01/1992 - "Efficacy of L-627, a new carbapenem, in the treatment of experimentally induced intra-abdominal infections in rats."
|2.||Urinary Tract Infections (Urinary Tract Infection)
01/01/2010 - "A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections."
12/01/2013 - "This multicenter, randomized, parallel-controlled clinical trial was conducted to compare the clinical efficacy, bacterial eradication rates and safety of biapenem and meropenem in the treatment of bacterial lower respiratory tract infections and urinary tract infections (UTIs) at nine centres in China. "
12/01/1994 - "1. L-627 at dose levels of 5.4 mg/kg to 12.4 mg/kg (daily doses of 16.2 mg/kg to 37.2 mg/kg) was administered by intravenous drip infusion 3 times daily for 5 to 7 days to 2 cases of pneumonia, 3 cases of skin and soft-tissue infections and 1 case of urinary tract infection for a total of 6 cases. "
01/01/2002 - "In randomised, nonblind or double-blind clinical trials, biapenem showed good clinical and bacteriological efficacy (similar to that of imipenem/ cilastatin) in the treatment of adult patients with intra-abdominal infections, lower respiratory infections or complicated urinary tract infections. "
07/01/1994 - "Those patients who responded well to L-627 treatment included 11 children with pneumonia, 1 with scarlet fever, 1 with cervical lymphadenitis, 2 with cellulitis, 6 with urinary tract infection. "
12/01/1994 - "L-627 was effective in a case of purulent meningitis due to PC-insensitive S. "
12/01/1994 - "4. Concentrations of L-627 in cerebrospinal fluid were determined in 2 cases of purulent meningitis. "
12/01/1994 - "Cerebrospinal fluid levels of biapenem in two patients with purulent meningitis were 0.88 and 2.72 micrograms/ml, and the penetration rates were 3.7 to 8.3%. "
07/01/1994 - "The transferability of biapenem (L-627) to cerebrospinal fluid (CSF) was studied employing rabbits with experimental meningitis caused by Staphylococcus aureus. "
07/01/1994 - "[Transferability of biapenem (L-627) to cerebrospinal fluid in rabbits with meningitis caused by Staphylococcus aureus]."
|4.||Communicable Diseases (Infectious Diseases)
07/01/1994 - "From these results, it has been concluded that L-627 is a safe and effective drug to be used in treatment of pediatric infectious diseases."
07/01/1994 - "The results indicate that L-627 is effective and safe in children with acute infectious diseases and suggest the usefulness of L-627 in the pediatric field."
11/01/1999 - "[Clinical evaluation of biapenem in various infectious diseases]."
07/01/1994 - "L-627 was administered intravenously to 11 patients with ages ranging 2 months to 10 years and 5 months with acute infectious diseases. "
11/01/1999 - "The clinical usefulness of injectable biapenem (BIPM) was examined for various infectious diseases in the fields of internal medicine, urology, surgery, orthopedics, obstetrics and gynecology, otorhinolaryngology, ophthalmology, dermatology, oral surgery, and plastic surgery. "
|5.||Ventilator-Associated Pneumonia (Pneumonia, Ventilator Associated)
09/01/2013 - "In vivo efficacy of biapenem with ME1071, a novel metallo-β-lactamase (MBL) inhibitor, in a murine model mimicking ventilator-associated pneumonia caused by MBL-producing Pseudomonas aeruginosa."
08/01/2012 - "We used a murine model to examine the efficacy of biapenem against ventilator-associated pneumonia (VAP) caused by P. "
08/01/2012 - "In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa."
|2.||imipenem drug combination cilastatin (Primaxin)
|7.||Penicillin-Binding Proteins (Penicillin-Binding Protein)
|3.||Oral Surgery (Maxillofacial Surgery)